Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?

No matter how you look at it, the FDA approval of Kisunla is big for Eli Lilly.How does Eli Lilly (LLY 0.38%) follow up on gains of close to 60% in 2023 and so far in 2024? By winning a major U.S. Food and Drug Administration (FDA) approval.Last week, the FDA approved Lilly's Kisunla (donanemab) in treating early symptomatic Alzheimer's disease. Is Eli Lilly stock a no-brainer buy after this key FDA approval? How big is Lilly's FDA win?There are now eight FDA-approved treatments for Alzheimer's disease. Tha ...